You would like to read
- US FDA grants breakthrough designation for early-stage breast cancer detection blood test developed in India by Datar Cancer Genetics
- Masala King Dr Dhananjay Datar inaugurates 50th Al Adil Super Store in Dubai
- Harvard Business School online announces certificate course by Srikant Datar to help business leaders think differently
- Oil PSUs set up 101 PSA oxygen plants
- BAFTA Breakthrough India applications deadline extended by one week, allowing more time for Breakthrough' Aspirants to apply
Mumbai (Maharashtra) [India], February 15 (ANI/PR Newswire): Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Designation' for its blood test to detect early-stage prostate cancer. This is the second test from the Company that has received the Breakthrough Device Designation from the US FDA. Late last year, the company's breast cancer detection test became the first such test to receive the designation.
This is the first blood test for men which can detect early-stage prostate cancer with high accuracy. Men with serum PSA of more than 3 ng / mL can avail of this test in consultation with their physician. The test requires 5 ml blood and does not involve exposure to radiation or any of the discomforts of a digital rectal examination. The blood test is based on the detection of Circulating Tumor Cells (CTCs) specific to prostate adenocarcinoma. The test can detect early-stage prostate cancers with more than 99 per cent accuracy without any false positives. The test has been validated in large clinical studies involving healthy males and prostate cancer patients.
In India, about 35,000 men were detected with prostate cancer in 2020 and this number is slated to increase every year, as is the case for all cancers due to various risk factors. Unfortunately, most prostate cancer cases are detected at late stages (III or IV) where it has spread to other organs. In such cases, curative surgeries that can remove the cancerous tissue are not viable options, and treatment involves long-term administration of anticancer drugs to manage the disease. If detected at early stages where cancer has not spread out of the prostate, prostate cancer has a very high ( & gt;99 per cent) chance of being cured.
"About 75 per cent of prostate biopsies are benign and with foreknowledge, these could be potentially avoided. The new blood test by the Datar team will help Doctors decide precisely the patients who need a biopsy and who do not. This is a very significant scientific advancement in the complex field of liquid biopsies coming from India. I congratulate the Datar team for their exemplary work and achievement," said Dr Sewanti Limaye, Director of Medical and Precision Oncology and Oncology Research, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai.
"It is a landmark acknowledgement that the US FDA has recognized the potential benefits of our 'first in the world' prostate cancer detection test. The highly coveted 'Breakthrough Designation' is granted after very rigorous evaluation. We take great pride in the fact that this test has been wholly developed in India and by Indian scientists and clinicians. This is our ongoing contribution to the Prime Minister's 'Atmanirbhar Bharat' mission after the breakthrough breast cancer detection test and is further intended to augment the global fight against cancer," said Rajan Datar, Chairman of the Company.
Appreciably, getting the test does not involve having to go to any hospital or health centre and waiting for appointments. The blood collection for this test can be done in the convenience and privacy of one's home or office after which the patient can go about their routine work. From the patient's point of view, the whole process is very non-intrusive.
The test is already available in Europe and is CE marked. The Company is in discussions with several leading healthcare providers for ready accessibility in India.
Datar Cancer Genetics is a global oncology research and applications company that is spearheading the development of non-invasive technologies for improved detection, treatment and management of cancer. The Company's state-of-the-art cancer research centre is NABL, ISO, CAP and CLIA accredited. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.
Website: (https://trubloodprostate.com)
Photo: (https://mma.prnewswire.com/media/1746104/Datar_Cancer_Genetics.jpg)
Logo: (https://mma.prnewswire.com/media/1572835/Datar_Cancer_Genetics_Logo.jpg)
This story is provided by PR Newswire. ANI will not be responsible in any way for the content of this article. (ANI/PR Newswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
